Gilteritinib

(Xospata®)

Gilteritinib

Drug updated on 11/15/2023

Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • To treat refractory or relapsed acute myeloid leukemia in adults with a FLT3 mutation as detected by an FDA-approved test.